Get the Stockscreener App
3.86
2.66%
0.10
After Hours:
3.84
-0.02
-0.52%
Adc Therapeutics Sa stock is traded at $3.86, with a volume of 2.60M.
It is up +2.66% in the last 24 hours and up +5.18% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.76
Open:
$3.83
24h Volume:
2.60M
Relative Volume:
2.80
Market Cap:
$490.96M
Revenue:
$81.36M
Net Income/Loss:
$-142.62M
P/E Ratio:
-3.2143
EPS:
-1.2009
Net Cash Flow:
$-146.97M
1W Performance:
+2.12%
1M Performance:
+5.18%
6M Performance:
-7.21%
1Y Performance:
+199.22%
1-Day Range:
$3.82
$4.13
1-Week Range:
$3.36
$4.13
52-Week Range:
$1.225
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.86 | 478.24M | 81.36M | -142.62M | -146.97M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
ADC Therapeutics Q1 2026 Earnings: Revenue Growth and ZYNLONTA MilestonesNews and Statistics - IndexBox
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT) - Seeking Alpha
ADC Therapeutics SA 2026 Q1ResultsEarnings Call Presentation (NYSE:ADCT) 2026-05-05 - Seeking Alpha
ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada - MarketBeat
ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript - Insider Monkey
ADC Therapeutics SA Q1 2026 Financial Results: Revenue, Losses, and Forward-Looking Statements - Minichart
ADC Therapeutics to Host First Quarter 2026 Financial Results Co - GuruFocus
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call - Benzinga
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics Reports Narrower Q1 2026 Loss, Beats Estimates - AlphaStreet
ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M - Stock Titan
ADC Therapeutics Q1 2026: $0.13/share Loss Beats Estimates — Deep Dive - AlphaStreet
ADC Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ADC Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Reports Q1 2026 Financial Results and Updates – NYSE: ADCT - Minichart
ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June - MSN
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ADC Therapeutics Q1 Earnings Call Highlights - MarketBeat
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
ADC Therapeutics : (ADCT 1Q 2026 Earnings) - marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued - ChartMill
The biopharmaceutical company ADC Therapeutics SA recently disclosed its latest financial data, showing that as of March 31, 2026, the company's cash and cash equivalents totaled 231 million USD. - Exchange Bitget
ADC Therapeutics (NYSE:ADCT) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q1 2026 Earnings - Quiver Quantitative
ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028 - Stock Titan
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
Earnings Scheduled For May 4, 2026 - Benzinga
MSN Money - MSN
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Australia
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - ChartMill
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 - Nasdaq
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics rises on $60M PIPE financing - MSN
ADC Therapeutics schedules May 4 webcast on Q1 results and operations - Stock Titan
Redmile Group (NASDAQ: ADCT) reports 9.9% stake after SPV reorg - Stock Titan
ADC Therapeutics S.A. Investigated by the Portnoy Law Firm - GlobeNewswire
ADC Therapeutics SA ($ADCT) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, equity plan and capital changes at ADC Therapeutics (ADCT) - Stock Titan
ADC Therapeutics (NASDAQ: ADCT) adds SILV Fund as selling shareholder - Stock Titan
ADC Therapeutics (NYSE:ADCT) Shares Up 11.8%Still a Buy? - MarketBeat
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - ADVFN
ADC Therapeutics (NYSE: ADCT) to hold virtual AGM June 1; votes on capital and pay - Stock Titan
Aug Spikes: Can ADC Therapeutics SA continue delivering strong returns2026 Key Lessons & High Accuracy Trade Signal Alerts - baoquankhu1.vn
ADC Therapeutics SA $ADCT Stock Holdings Raised by JPMorgan Chase & Co. - MarketBeat
ADCT.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):